Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
      Description

      This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

      Conditions
      Advanced Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Mycosis FungoidesRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeRefractory Grade 1 Follicular LymphomaRefractory Grade 2 Follicular LymphomaRefractory Grade 3a Follicular LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaStage IB Mycosis Fungoides AJCC v7Stage II Mycosis Fungoides AJCC v7Stage III Cutaneous T-Cell Non-Hodgkin LymphomaStage III Mycosis Fungoides AJCC v7Stage IV Cutaneous T-Cell Non-Hodgkin LymphomaStage IV Mycosis Fungoides AJCC v7
      Talk to us
      COMPLETED
      Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
      Description

      This phase II trial studies how well pembrolizumab and interferon gamma-1b work in treating patients with stage IB-IVB mycosis fungoides and Sezary syndrome that has come back (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Interferon gamma-1b may boost the immune system activity. Giving pembrolizumab and interferon gamma-1b together may work better in treating patients with stage IB-IVB mycosis fungoides and Sezary syndrome.

      Conditions
      Metastatic Myxoid LiposarcomaMetastatic Round Cell LiposarcomaMetastatic Synovial SarcomaRecurrent Mycosis Fungoides and Sezary SyndromeRefractory Mycosis Fungoides and Sezary SyndromeStage IB Mycosis Fungoides and Sezary Syndrome AJCC v7Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7Unresectable Synovial Sarcoma
      Talk to us
      COMPLETED
      O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma
      Description

      This phase I/II trial studies the side effects and best dose of carmustine when given together with O6-benzylguanine and to see how well they work in treating patients with stage IA-IIA cutaneous T-cell lymphoma. Drugs used in chemotherapy, such as carmustine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. O6-benzylguanine may help carmustine work better by making cancer cells more sensitive to the drug. Giving O6-benzylguanine with carmustine may kill more cancer cells.

      Conditions
      Recurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage I Mycosis Fungoides and Sezary Syndrome AJCC v7Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
      Talk to us